Avstera Therapeutics Corp.

Avstera Therapeutics is a clinical-stage biotechnology company that develops novel immunomodulatory therapeutics to address significant unmet needs in oncology and other disease areas. The company's lead candidate, AVS100, is an orally bioavailable, highly selective HDAC6 inhibitor designed to treat locally advanced or metastatic solid tumors. AVS100 works by suppressing the polarization of tumor-associated macrophages toward pro-tumoral phenotypes, an immunosuppressive cell population often found in the tumor microenvironment. By modulating these cells, the therapy aims to enhance the immune response, particularly in combination with existing treatments like PD-1 inhibitors. Additionally, the company is building a proprietary pipeline that includes next-generation HDAC6 inhibitors for cardiometabolic indications and the MyeloNex discovery platform for identifying novel molecular targets in myeloid cells.

These advancements are significant for cancer patients who have limited treatment options or have developed resistance to standard immunotherapies. By targeting the immune mechanisms that contribute to tumor progression and therapy resistance, Avstera seeks to provide more effective and easily administered clinical solutions. The company's approach is supported by preclinical studies demonstrating substantial efficacy in reducing tumor growth and a favorable safety profile. Founded in 2021 and headquartered in the Philadelphia area, Avstera operates as a J&J JLABS resident company and is actively transitioning into clinical trials to validate its therapeutic candidates in human patients. Through its focus on foundational cell biology and innovative platform technologies, the company aims to impact a broad range of challenging clinical indications.